FDC LTD.

Nandan Mohan Chandavarkar has filed a disclosure under SEBI (SAST) Regulations, 2011, detailing a change in his shareholding in FDC Limited. The transaction, an off-market inter-se transfer by way of gift without consideration, occurred on June 24, 2026. Prior to the transaction, his holding was 50,41,086 shares (3.10% of total capital). After the transaction, his direct holding is 11,000 shares (0.01%). The disclosure also covers holdings of associated trusts and other promoter group members, indicating a shift in direct and indirect control within the promoter group.

FDC Ltd has submitted its Business Responsibility and Sustainability Report (BRSR) for the financial year 2025-26, as per SEBI regulations. The report details the company's commitment to environmental, health, and safety standards, including medical assistance and periodic health checkups for employees. FDC Ltd confirms there are no significant orders from regulators or courts that would impact its going concern status. The company also expressed gratitude to its stakeholders, including employees, government authorities, financial institutions, and the medical fraternity, for their continued support and cooperation.

FDC Ltd has released its Annual Report for the financial year 2025-26, in compliance with SEBI Listing Regulations. The report is accessible on the company's website. The 86th Annual General Meeting (AGM) is scheduled for Thursday, September 24, 2026, at 10:00 a.m. IST, to be held through Video Conferencing/Other Audio-Visual Means. The cut-off date for determining members eligible to vote on AGM resolutions is Wednesday, September 16, 2026. Remote e-voting will be open from Monday, September 21, 2026, at 09:00 a.m. IST, until Wednesday, September 23, 2026, at 05:00 p.m. IST. The report outlines the company's strategic vision, commitment to wellness, and corporate governance, including changes in board and key managerial personnel.

FDC Ltd has announced the details for its 86th Annual General Meeting (AGM) for the financial year 2025-26. The AGM will be held on Thursday, September 24, 2026, at 10:00 a.m. IST via Video Conferencing/Other Audio-Visual Means. Key agenda items include the adoption of audited standalone and consolidated financial statements for FY 2025-26, the re-appointment of Executive Director Mr. Ashok Anand Chandavarkar, and the ratification of remuneration for the Cost Auditor, M/s. GMVP & Associates LLP, for FY 2026-27. The cut-off date for determining voting eligibility is September 16, 2026, with remote e-voting available from September 21 to September 23, 2026. The Annual Report for FY 2025-26 is also available on the company's website.

FDC Ltd has received an interim stay from the High Court of Delhi concerning a notice from FSSAI Maharashtra regarding the seizure of stock. The court has granted the company eight months to exhaust its existing stock labeled 'electrolyte'/'electrolyte drink' and to update its product labels. FDC Ltd stated that this development has no material adverse impact on its financials, operations, or other activities. The company had filed a writ petition seeking relief after the initial stock seizure.

FDC Ltd's subsidiary, FDC International Ltd., has secured Marketing Authorisation from the UK's Medicines and Healthcare products Regulatory Agency (MHRA) for its Atropine 1.0% w/v Eye Drops, Solution. This approval allows the product to be marketed in the United Kingdom, marking a significant step for the company's international pharmaceutical presence and product portfolio expansion in the ophthalmic segment.

FDC Limited announced its unaudited financial results for Q1 FY27, reporting a 3.0% year-on-year increase in consolidated revenue from operations to ₹668 crores. EBITDA grew by 1.9% to ₹143 crores, while Profit Before Tax (PBT) and Profit After Tax (PAT) saw increases of 9.4% and 9.2% respectively. Earnings Per Share (EPS) rose to ₹8.14 from ₹7.45 in the prior year. The growth was primarily driven by strong performance in International Formulations, especially the US business, which surged 118.4%. Domestic Formulations and APIs experienced a slight decline. The company also received US FDA approval for Cefixime for Oral Suspension.

FDC Limited announced its unaudited standalone and consolidated financial results for the quarter ended June 30, 2026, following a Board of Directors meeting held on August 05, 2026. The board also granted in-principle approval for an investment of up to Rs. 45 Lakhs for a minimum 26% equity stake in Netra Green Energy Private Limited, a subsidiary of Sunsure Energy Private Limited. This investment is intended for power procurement under a Group Captive Solar Project for the company's API manufacturing plant in Roha and is subject to due diligence and regulatory approvals.

FDC Ltd's consolidated Q1 FY27 (quarter ended June 30, 2026) print is profit-led rather than volume-led: consolidated PAT rose 9.2% YoY to ₹132.49 Cr on revenue growth of just 3.0% YoY to ₹667.69 Cr, with net margin expanding to 18.52% from 17.74% a year ago. Operating margin (PBT before exceptional items, adjusted for finance cost, depreciation and other income, over revenue) held roughly flat at 21.42% versus 21.64% a year ago — so the earnings growth was driven mainly by a 34.2% YoY jump in other income (₹47.65 Cr vs ₹35.50 Cr) rather than by core operating leverage. Sequentially the quarter looks stronger, with PAT up 28.1% QoQ and revenue up 14.2% QoQ against a soft Q4 FY26, but per our reading convention that QoQ move is supporting detail, not the headline story. Standalone growth diverges sharply from the consolidated picture: standalone revenue grew 20.8% YoY to ₹655.10 Cr against consolidated revenue growth of only 3.0% YoY, implying the net inter-company/subsidiary contribution — which the auditors describe as immaterial to the group this quarter at ₹17.21 Cr of pre-consolidation subsidiary revenue — was unusually elevated in the year-ago quarter. Readers comparing the standalone and consolidated releases should expect the topline growth rates to look very different this quarter for that reason; standalone PAT itself grew a similar 8.0% YoY to ₹132.02 Cr, in line with the consolidated PAT trend. We have no analyst consensus estimates on record and a web search turned up no published Q1 FY27 preview or brokerage estimate for FDC specifically, so vsStreet is marked unknown rather than assumed. Similarly, there is no formal management guidance on record for this quarter — company records and search show none — so vsGuidance is also unknown. No separate management press release with qualitative commentary was available in the context to cross-check against the numbers; the filing itself is limited to the regulatory disclosure and financial statements. Alongside the results, the board approved an in-principle investment of up to ₹45 lakh for a minimum 26% equity stake in Netra Green Energy Pvt Ltd to secure captive solar power for the company's Roha API manufacturing plant — a small capital-allocation item, immaterial to this quarter's earnings. Separately, Maharashtra FDA seized stock and samples of the company's 'Enerzal' brand on June 4, 2026; the filings reviewed do not quantify any financial impact, so it is flagged here as a monitorable rather than a confirmed hit to the numbers.

FDC Ltd has announced that its Board of Directors will convene on Wednesday, August 5, 2026. The primary agenda item for this meeting is to consider and approve the unaudited standalone and consolidated financial results for the first quarter ended June 30, 2026. In line with the company's insider trading policy and SEBI regulations, the trading window for directors and designated persons has been closed since July 1, 2026, and will reopen 48 hours after the financial results are declared.